MNKD vs INSM

For growth investors, Insmed Incorporated (INSM) is the stronger pick with 66.

7% revenue growth year-over-year, versus 22. 2% for MannKind Corporation (MNKD). MannKind Corporation (MNKD) offers the better valuation at 178. 0x trailing P/E (218. 4x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Insmed Incorporated (INSM) delivered a total return of +321.

8%, compared to -12. 7% for MannKind Corporation (MNKD). Over 10 years, the gap is even starker: INSM returned +1134% versus MNKD's -46. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Insmed Incorporated (INSM) is the lower-risk stock at 0.

54β versus MannKind Corporation's 0. 90β — meaning MNKD is approximately 66% more volatile than INSM relative to the S&P 500.

By revenue growth (latest reported year), Insmed Incorporated (INSM) is pulling ahead at 66.

7% versus 22. 2% for MannKind Corporation (MNKD). On earnings-per-share growth, the picture is similar: Insmed Incorporated grew EPS -15. 3% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MannKind Corporation (MNKD) is the more profitable company, earning 1.

7% net margin versus -210. 5% for Insmed Incorporated — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus -205. 6% for INSM. At the gross margin level — before operating expenses — MNKD leads at 82. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MNKD: 96.

6% to $7. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Insmed Incorporated (INSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

54), +1134% 10Y return). Both have compounded well over 10 years (INSM: +1134%, MNKD: -46. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.